Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eurofins Scientific SEERFSF +5.19%77 Debt-to-Equity is 0.98 as of Dec. 2025, which is 15% above its 10-year median of 0.85. GuruFocus rates ERFSF with a GF Score™ of 77/100 and a GF Value™ of $78.14 (Fairly Valued). The stock has 7 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks worse than 82.51% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Eurofins Scientific SE's Debt-to-Equity or its related term are showing as below:
ERFSF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.59 Med: 0.85 Max: 1.25
Current: 0.98
During the past 13 years, the highest Debt-to-Equity Ratio of Eurofins Scientific SE was 1.25. The lowest was 0.59. And the median was 0.85.
ERFSF's Debt-to-Equity is ranked worse than 82.51% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.33
vs ERFSF: 0.98
Eurofins Scientific SE (OTCPK:ERFSF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Eurofins Scientific SE Debt-to-Equity Related Terms
Eurofins Scientific SE Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Eurofins Scientific SE's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ERFSF vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Eurofins Scientific SE's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins Scientific SE (ERFSF) has a Debt-to-Equity of 0.98 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Eurofins Scientific SE and its competitors. This is 15% above median its historical median of 0.85. Over the past decade, Eurofins Scientific SE's Debt-to-Equity has ranged from 0.59 to 1.25. According to the industry distribution chart, Eurofins Scientific SE ranks #151 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 82.5%.
Is Eurofins Scientific SE's Debt-to-Equity too high?
Eurofins Scientific SE's current Debt-to-Equity of 0.98 is 15% above median its 10-year median of 0.85. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 1.25. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. Eurofins Scientific SE's value of 0.98 is 197% above this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #151 out of 183 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Eurofins Scientific SE has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #151 out of 183 companies for Debt-to-Equity. This places Eurofins Scientific SE in the lower half of its industry. The industry median Debt-to-Equity is 0.33. Eurofins Scientific SE's value of 0.98 is 197% above this benchmark. Historically, Eurofins Scientific SE's own Debt-to-Equity has ranged from 0.59 to 1.25 over the past decade. While the company's 10-year median is 0.85 vs. the industry median of 0.33, Eurofins Scientific SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current Debt-to-Equity of 0.98 is 197% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Eurofins Scientific SE and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current Debt-to-Equity is 0.98, which is 15% above median its own 10-year median of 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $78.14, compared to a current price of $80.42 — trading 2.9% above its estimated fair value. The current Debt-to-Equity is 0.98, which is 15% above median its 10-year median of 0.85 and 197% above the Medical Diagnostics & Research industry median of 0.33. Eurofins Scientific SE's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current Debt-to-Equity is 0.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $80.42 is trading 2.9% above its estimated GF Value™ of $78.14.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
Debt-to-Equity: 0.98 (15% above median its 10-year median of 0.85)
GF Value™: $78.14 vs. price of $80.42 (2.9% above fair value)
Industry Position: 197% above the Medical Diagnostics & Research median (#151 of 183)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
77GF Score
Get the complete analysis for ERFSF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
